Tislelizumab-related enteritis successfully treated with adalimumab: A case report

BACKGROUND With programmed death-1 (PD-1) inhibitors becoming the standard treatment for lung cancer, PD-1-related adverse reactions and treatment have gradually become prominent. CASE SUMMARY First reported case of tislelizumab-related enteritis successfully treated with adalimumab 40mg every 2 wk for 3 times in an advanced lung cancer patient who received first-line tislelizumab/pemetrexed/carboplatin for 4 cycles. The patient continued receiving the treatment of pemetrexed/carboplatin after symptoms, abdominal computed tomography and colonoscopy improved, significant diarrhea was not occurred. CONCLUSION Adalimumab can be an effective treatment option for patients with PD-1 antibody related enteritis if they do not respond well to glucocorticoid treatment.

[1]  Yi-long Wu,et al.  Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC) , 2020, Expert opinion on investigational drugs.

[2]  A. Tursi.  Immune checkpoint inhibitors-induced acute diverticulitis. , 2020, European journal of gastroenterology & hepatology.

[3]  Yi-long Wu,et al.  Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study , 2020, Journal for immunotherapy of cancer.

[4]  J. Desai,et al.  Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors , 2020, Journal for immunotherapy of cancer.

[5]  Li Zhang,et al.  Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab‐related colitis , 2020, Thoracic cancer.

[6]  Matthew J. Frigault,et al.  NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  R. Elstrom,et al.  Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study , 2019, Leukemia.

[8]  Xiaomin Song,et al.  The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions , 2018, Cancer Immunology, Immunotherapy.

[9]  I. Karydis,et al.  Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis , 2018, Rheumatology advances in practice.

[10]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[11]  Bengt Mannervik,et al.  Exploring sequence-function space of a poplar glutathione transferase using designed information-rich gene variants , 2017, Protein engineering, design & selection : PEDS.

[12]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  D. Fisher,et al.  Immune and molecular correlates in melanoma treated with immune checkpoint blockade , 2017, Cancer.

[14]  W. Miller,et al.  Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. , 2017, The New England journal of medicine.

[15]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[16]  J. Kirkwood,et al.  Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma , 2015, Journal of Immunotherapy for Cancer.

[17]  T. Schoeb,et al.  Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis , 2015, Proceedings of the National Academy of Sciences.

[18]  B. Wiedenmann,et al.  Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[19]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.